Lin Shou-Yean Grace, Desmond Edward P
California Department of Public Health, Richmond, CA, USA.
California Department of Public Health, Richmond, CA, USA.
Clin Lab Med. 2014 Jun;34(2):297-314. doi: 10.1016/j.cll.2014.02.005.
Molecular drug susceptibility testing (MDST) provides rapid diagnosis of tuberculosis (TB) and detection of drug resistance with commendable sensitivity and specificity. MDST reduces unnecessary isolation or treatment, when a negative result for TB is obtained. Because of the possibility of false detection of rifampin resistance by probe-based MDST, confirmation by sequencing is recommended, especially in regions where the prevalence of resistance is low. Revealing mutation identity by sequencing offers opportunities to study drug minimum inhibitory concentrations for each mutation. Such information enables prediction of resistance levels, and may be helpful in formulating optimal regimens, when treatment options are limited.
分子药敏试验（MDST）能快速诊断结核病（TB）并检测耐药性，具有良好的敏感性和特异性。当MDST结果为阴性时，可减少不必要的隔离或治疗。由于基于探针的MDST可能会错误检测利福平耐药性，因此建议进行测序确认，尤其是在耐药率较低的地区。通过测序揭示突变特征为研究每种突变的药物最低抑菌浓度提供了机会。这些信息能够预测耐药水平，在治疗选择有限时，可能有助于制定最佳治疗方案。
